January 17, 2020 Alex Hogan/STAT
G ood morning. Elizabeth Cooney here again, channeling Ed Silverman as another week draws to a close, that treasured signal to daydream about weekend plans. This weekend is a long one, as we here in the U.S. will observe Martin Luther King Jr. Day on Monday. Ed will be back on the Pharmalot campus and Pharmalittle will be back in his hands on Tuesday. Some news to tide you over until then:
A Republican member of the Federal Trade Commission on Thursday expressed support for allowing Medicare to directly negotiate the price of prescription medicines, a noteworthy break from GOP orthodoxy from a Trump administration appointee, STAT reports. The remarks from Christine Wilson, a business executive who President Trump appointed to the FTC in 2018, come as Washington remains split on how to tackle high drug prices and whether to allow Medicare to negotiate directly. Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months! Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What's included? The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology